BHARAT-1: A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics (clinicaltrials.gov) - Apr 18, 2026 - P1 | N=27 | Terminated | Sponsor: Aurigene Discovery Technologies Limited | N=80 ➔ 27 | Recruiting ➔ Terminated; Patient recruitment problems.
Enrollment change • First-in-human • Trial termination • Acute Myelogenous Leukemia • B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Leukemia • Lymphoma • Marginal Zone Lymphoma • Myelodysplastic Syndrome • Non-Hodgkin's Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • Solid Tumor
|